2 transcripts
IMCR
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
is a way to measure independence of radiographic, but also looking at treatment beyond progression because this is where the investigator sees the patient
IMCR
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
in two independent trials. So when it comes to uveal melanoma, ctDNA, we have really strong confidence. With cutaneous melanoma, we have emerging
- Prev
- 1
- Next